SAB BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
SAB BIOTHERAPEUTICS, INC. (SABS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.87 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $2.87, a 99.31% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $3.61.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $1.92, a 11.93% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $1.44, a 55.42% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.99, a 33.44% decline from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $2.99, a 39.35% decline from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $4.93, a 36.79% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $7.80, a 45.52% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.87 10-Q · filed 2026-08-06 | $3.57 10-Q · filed 2026-08-06 | ||||||
| 2026-03-31 | $3.61 10-Q · filed 2026-05-12 | |||||||
| 2025-12-31 | $1.99 10-K · filed 2026-03-09 | |||||||
| 2025-09-30 | $1.92 10-Q · filed 2025-11-14 | $1.92 10-Q · filed 2025-11-14 | ||||||
| 2025-06-30 | $1.44 10-Q · filed 2026-08-06 | $1.44 10-Q · filed 2026-08-06 | ||||||
| 2024-12-31 | $2.99 10-K · filed 2026-03-09 | |||||||
| 2024-09-30 | $2.18 10-Q · filed 2025-11-14 | $2.99 10-Q · filed 2025-11-14 | ||||||
| 2024-06-30 | $3.23 10-Q · filed 2025-08-07 | $3.93 10-Q · filed 2025-08-07 | ||||||
| 2024-03-31 | $3.94 10-Q · filed 2025-05-09 | |||||||
| 2023-12-31 | $4.93 10-K · filed 2025-03-31 | |||||||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $4.09 10-Q · filed 2024-11-06 | $0.41 10-Q · filed 2023-11-13 | |||||
| 2023-06-30 | $5.72 10-Q · filed 2024-08-08 | $0.57 10-Q · filed 2023-08-21 | $4.09 10-Q · filed 2024-08-08 | $0.41 10-Q · filed 2023-08-21 | ||||
| 2023-03-31 | $3.86 10-Q · filed 2024-05-20 | $0.39 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | $7.80 10-K · filed 2024-03-29 | $0.78 10-K · filed 2023-04-14 | ||||||
| 2022-09-30 | $0.57 10-Q · filed 2023-11-13 | $0.78 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | $1.79 10-Q · filed 2023-08-21 | $1.76 10-Q · filed 2023-08-21 | ||||||
| 2022-03-31 | $3.88 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | $5.36 10-K/A · filed 2023-04-28 | |||||||
| 2021-09-30 | $5.21 10-Q · filed 2022-11-14 | |||||||
| 2021-06-30 | $5.40 10-Q · filed 2022-08-10 | $5.21 10-Q · filed 2022-08-10 | ||||||
| 2021-03-31 | $4.34 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | $3.44 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |